You just read:

Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

News provided by

Sirnaomics, Inc.

Feb 06, 2017, 09:00 ET